New Potent Inhibitor of Transforming Growth Factor-Beta (TGFβ) Signaling that is Efficacious against Microsatellite
Daniele V F Tauriello1,2,3, Elena Sancho1,2, Daniel Byrom1
1Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 10, Barcelona 08028, Spain.
Abstract:
Blockade of the TGFβ signaling pathway has emerged from preclinical studies as a potential treatment to enhance the efficacy of immune checkpoint inhibition in advanced colorectal cancer (CRC) and several other types of cancer. However, clinical translation of first-generation inhibitors has shown little success. Here, we report the synthesis and characterization of HYL001, a potent inhibitor of TGFβ receptor 1 (ALK5), that is approximately 9 times more efficacious than the structurally related compound galunisertib, while maintaining a favorable safety profile. HYL001 in combination with immune checkpoint blockade (anti-PD1) eradicates liver metastases generated in mice by microsatellite stable, aggressive colorectal cancer tumors at doses where galunisertib is ineffective.
Insights
A new drug, HYL001, effectively targets the TGFβ pathway to boost cancer immunotherapy. In preclinical models of colorectal cancer, HYL001 combined with anti-PD1 therapy eradicated liver metastases, showing promise for advanced disease.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Transforming growth factor beta (TGFβ) signaling is a key target for enhancing cancer immunotherapy.
- Previous TGFβ inhibitors have faced challenges in clinical translation for advanced cancers like colorectal cancer (CRC).
Purpose of the Study:
- To synthesize and characterize HYL001, a novel and potent inhibitor of TGFβ receptor 1 (ALK5).
- To evaluate the efficacy of HYL001 in combination with immune checkpoint blockade (anti-PD1) in preclinical models of aggressive colorectal cancer.
Main Methods:
- Synthesis and characterization of HYL001, a TGFβ receptor 1 (ALK5) inhibitor.
- Comparative efficacy study of HYL001 versus galunisertib in combination with anti-PD1 therapy.
- Assessment of treatment outcomes in mouse models of microsatellite stable colorectal cancer with liver metastases.
Main Results:
- HYL001 demonstrated approximately 9 times greater efficacy than galunisertib, with a favorable safety profile.
- The combination of HYL001 and anti-PD1 therapy eradicated liver metastases in aggressive colorectal cancer models.
- HYL001 was effective at doses where galunisertib showed no significant effect.
Conclusions:
- HYL001 represents a potent and potentially safer TGFβ inhibitor compared to existing agents.
- The combination of HYL001 with immune checkpoint inhibitors shows significant therapeutic potential for advanced colorectal cancer, particularly in overcoming treatment resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy